Contraception
Volume 77, Issue 2 , Pages 122-129 , February 2008

Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials

  • Janneke H.H.M. van de Wijgert

      Affiliations

    • Academic Medical Center, Center for Poverty-related Communicable Diseases, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands
    • Population Council, One Dag Hammerskjold Plaza, New York, NY 10017, USA
    • Corresponding Author InformationCorresponding author. Academic Medical Center, Center for Poverty-related Communicable Diseases, PO Box 22700, 1100 DE Amsterdam, The Netherlands. Tel.: +31 20 5663044.
    • ,
  • Peter H. Kilmarx

      Affiliations

    • Population Council, One Dag Hammerskjold Plaza, New York, NY 10017, USA
    • National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 0333, USA
    • ,
  • Heidi E. Jones

      Affiliations

    • Population Council, One Dag Hammerskjold Plaza, New York, NY 10017, USA
    • Department of Ob/Gyn, Columbia University Medical Center, New York, NY 10032, USA
    • ,
  • John M. Karon

      Affiliations

    • Emergint Corp., Louisville, KY 40206, USA
    • ,
  • Supaporn Chaikummao

      Affiliations

    • Population Council, One Dag Hammerskjold Plaza, New York, NY 10017, USA

Received 23 August 2007 ,Accepted 15 October 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ None of the authors have a commercial association with Carraguard nor other conflicts of interest. Carraguard is being developed by the Population Council, which is a not-for-profit nongovernmental organization, under a US Food and Drug Administration Investigational New Drug Application (IND 58,441). Financial support for this study was provided by the US Centers for Disease Control and Prevention and the Bill and Melinda Gates Foundation. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the US Centers for Disease Control and Prevention.

PII: S0010-7824(07)00460-X

doi: 10.1016/j.contraception.2007.10.006

Contraception
Volume 77, Issue 2 , Pages 122-129 , February 2008

Article Tools

* Image Usage & Resolution